The DiversitabTM system produces target specific high titer fully human polyclonal IgG
immunoglobulins from transchromosomic (Tc) bovines shown to be safe and effective …

Influenza remains a global health risk and challenge. Currently, neuraminidase (NA)
inhibitors are extensively used to treat influenza, but their efficacy is compromised by the …

Influenza A virus continuously infects humans and the antigenic shifts of this respiratory virus
enable it to cross the species barrier, threatening public health with the risk of pandemics …

Seasonal epidemics caused by antigenic variations in influenza A virus remain a public
health concern and an economic burden. The isolation and characterization of broadly …

H1N1 influenza virus is a significant global public health concern. Monoclonal antibodies
(mAbs) targeting specific viral proteins such as hemagglutinin (HA) have become an …

Antibody-dependent cell-mediated cytotoxicity (ADCC) bridges innate and adaptive
immunity, and it involves both humoral and cellular immune responses. ADCC has been …

Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against avian
influenza virus subtypes, including H7N9 and H5N1, have been detected in human sera …

Background Human antibodies that interfere with the biological activity of haemagglutinins
(HAs) of influenza viruses have high potential as an antiviral agent. Methods Human single …

Many broadly reactive human monoclonal antibodies against the hemagglutinin (HA) stem
of influenza A virus have been developed for therapeutic applications. These antibodies …

Hemagglutinin (HA), the major antigen on the surface of influenza viruses, is the primary
target for neutralizing antibodies and vaccine design. However, frequent mutations in this …